Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia.
about
Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical ApplicationsMeasurable residual disease testing in acute myeloid leukaemia.Early reduction of WT1 transcripts during induction chemotherapy predicts for longer disease free and overall survival in acute myeloid leukemia.Significance of persistent cytogenetic abnormalities on myeloablative allogeneic stem cell transplantation in first complete remission.Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm.Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantationAssessment of the consistency and robustness of results from a multicenter trial of remission maintenance therapy for acute myeloid leukemia.Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia.Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.Minimal Residual Disease in AML: Why Has It Lagged Behind Pediatric ALL?Comparative analysis of different approaches to measure treatment response in acute myeloid leukemiaPrognostic impact of discordant results from cytogenetics and flow cytometry in patients with acute myeloid leukemia undergoing hematopoietic cell transplantation.Minimal residual disease detection in pediatric acute myeloid leukemia: does flow cytometry score a point over molecular biology?Measurements of treatment response in childhood acute leukemia.Postremission sequential monitoring of minimal residual disease by WT1 Q-PCR and multiparametric flow cytometry assessment predicts relapse and may help to address risk-adapted therapy in acute myeloid leukemia patients.Continued improvement in survival of acute myeloid leukemia patients: an application of the loss in expectation of lifePersistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantationMinimal residual disease as a predictive factor for relapse after allogeneic hematopoietic stem cell transplant in adult patients with acute myeloid leukemia in first and second complete remission.Pre- and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia.Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission.Effect of measurable ('minimal') residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia.Minimal residual disease quantitation in acute myeloid leukemiaReview of the relevance of aberrant antigen expression by flow cytometry in myeloid neoplasms.Predictive factors of relapse and survival in childhood acute myeloid leukemia: role of minimal residual disease.Molecular markers in acute myeloid leukaemia.Prognostic and therapeutic implications of minimal residual disease at the time of transplantation in acute leukemia.Autologous Stem Cell Transplantation in elderly Acute Myeloid LeukemiaClinical significance of minimal residual disease in patients with acute leukaemia undergoing haematopoietic stem cell transplantation.Brazilian guidelines on hematopoietic stem cell transplantation in acute myeloid leukemia.Tumor heterogeneity makes AML a "moving target" for detection of residual disease.Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia.Comparable outcomes between autologous and allogeneic transplant for adult acute myeloid leukemia in first CR.Absence of leukaemic CD34(+) cells in acute myeloid leukaemia is of high prognostic value: a longstanding controversy deciphered.Clinical analysis and optimization of postremission therapy for acute myeloid leukemia patients with minimal residual disease as determined by flow cytometryEffect of post-remission chemotherapy preceding allogeneic hematopoietic cell transplant in patients with acute myeloid leukemia in first remission.Bone marrow WT1 levels at diagnosis, post-induction and post-intensification in adult de novo AML.Minimal/measurable residual disease in AML: consensus document from ELN MRD Working Party.The Prognostic Significance of Measurable ("Minimal") Residual Disease in Acute Myeloid Leukemia.Minimal residual disease by either flow cytometry or cytogenetics prior to an allogeneic hematopoietic stem cell transplant is associated with poor outcome in acute myeloid leukemia.Patient-tailored analysis of minimal residual disease in acute myeloid leukemia using next-generation sequencing.
P2860
Q28073464-D1606AFC-68BB-43DC-84D1-D9725F8F6C66Q30234914-496C0B8E-E9AB-4C0B-93FB-07691F93DC98Q33829117-3A9E4E20-DBB5-43A4-BFED-4579A470777CQ33931553-D739D551-B83A-4498-B033-58443C78D79CQ34193514-A1E8FDB7-B3FA-4F49-B75F-17668CB79BD4Q34627218-530EEA75-D697-41ED-8784-5D7F71AF50F4Q34797782-12BCD402-0EEA-46EA-ABD0-5DC62D52D983Q34877613-AEA2C7A8-0D55-49D3-8E5E-CA83E2F0C4A9Q35209900-E5C04DE8-B572-4D42-A1CD-0E622ABE20DBQ35992927-B85AA77B-4345-4F28-BDF1-80ABF32484B7Q36290737-8A2E7B4A-3C1F-4D38-9710-D3ACB6F404FCQ36505822-B1ACC65D-919C-470D-B82F-638460446ADBQ36508284-21EAD3B8-C376-4310-8BE8-17CA44CD416DQ36513773-BB79B352-297D-41C2-9277-41E16788EF76Q36528379-CA8E9DE8-6903-48C1-9E23-6619218D5A29Q36633055-01287F7C-64E4-47DF-827A-F6F05483D73FQ36920398-C48737C0-4BEA-4073-8929-8C7027C4A895Q37016999-0D0E7216-D2C3-440B-9BFF-152C7C2E2C67Q37072126-564A7415-2AA1-447C-89CF-0EB276BEF3CDQ37151698-AD90B844-C0C2-4650-B1C4-C0BB7AAA2C6EQ37317800-DE722106-F74D-4465-AFA8-8D5B0D40D6EBQ37447344-236C5A31-B71E-4A3F-BC59-3745545DE341Q37850824-21CC02FE-6920-4F99-A014-E21907CC7A40Q37934964-4078C120-DB4D-48F9-89E0-38B826F56ED5Q38026007-84871BA3-49CC-4EDA-89A1-51F3511A5498Q38028808-B9DE5000-DCA3-4ADA-ABB5-11B9AA3AA612Q38090612-E2044FF1-C6F2-43D0-AB59-4E93648155B8Q38105123-F71105E2-9BFA-4404-8A55-CE03B94D0243Q38952815-D459797F-99DC-4445-BFDC-5941117BD792Q39327715-1CE103CE-B17E-41F5-AF35-151A3DB8722EQ39474999-4C3D3E35-07B8-4DE6-9BBF-EDEF1A333F51Q40064058-1A0E269C-B176-4336-8E80-C86F65947D31Q41646376-3FFB1718-A619-4DF4-BBD0-BFC1A7F085A3Q42108788-2E3F170E-32B5-43D7-8628-AE07033879BEQ42970797-243188CF-7935-4434-9674-CA9F78C03E3CQ46571589-0A8A8279-0DE5-4478-9397-3319E9AD0680Q47734674-EC3BE205-B2BD-4176-B743-843DF6FA1993Q47804815-71845C71-DCB2-42BA-8E41-C44668175B99Q48236706-A32F8817-9009-432E-A9D8-468158B12787Q50642627-029152CD-993A-44F2-B741-969F2B816C53
P2860
Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Toward optimization of postrem ...... s with acute myeloid leukemia.
@en
Toward optimization of postrem ...... s with acute myeloid leukemia.
@nl
type
label
Toward optimization of postrem ...... s with acute myeloid leukemia.
@en
Toward optimization of postrem ...... s with acute myeloid leukemia.
@nl
prefLabel
Toward optimization of postrem ...... s with acute myeloid leukemia.
@en
Toward optimization of postrem ...... s with acute myeloid leukemia.
@nl
P2093
P50
P356
P1476
Toward optimization of postrem ...... ts with acute myeloid leukemia
@en
P2093
Adriano Venditti
Benedetta Neri
Chiara Sarlo
Daniela Venditti
Emanuele Ammatuna
Francesco Lo Coco
Licia Ottaviani
Luca Maurillo
Manuela Rizzo
Micol Quaresima
P304
P356
10.1200/JCO.2007.15.9814
P407
P50
P577
2008-07-07T00:00:00Z